Evaluation of ruxolitinib, a JAK inhibitor, in multiple myeloma
A new research perspective titled "Preclinical and clinical evaluation of the Janus Kinase inhibitor ruxolitinib in multiple myeloma" has been published in Oncotarget.
Feb 7, 2024
0
40
MeSH tree: D08.811.913.696.620.682.725
A new research perspective titled "Preclinical and clinical evaluation of the Janus Kinase inhibitor ruxolitinib in multiple myeloma" has been published in Oncotarget.
Feb 7, 2024
0
40
Chronic obstructive pulmonary disease (COPD) is the third-leading cause of death worldwide. It is marked by lung damage that is lasting and incurable, leaving lung transplantation as the only viable treatment option. Unfortunately, ...
Jan 5, 2024
0
40
QUT scientists have discovered a promising new therapy for a deadly type of endometrial cancer that has a poor prognosis if the cancer spreads or returns after initial treatment, a plight that affects 15%–20% of endometrial ...
Dec 13, 2023
0
42
Researchers at Case Western Reserve University and University Hospitals have identified an enzyme that blocks insulin produced in the body—a discovery that could provide a new target to treat diabetes.
Dec 8, 2023
0
96
In the late 1970s, the relationship between the c-Src gene and cancer was discovered. The first oncogene was identified. Since then, c-Src has been found to be overactivated in half of colon, liver, lung, breast, prostate ...
Oct 31, 2023
0
72
A new study from researchers at the University of British Columbia's Faculty of Medicine reveals a direct link between high insulin levels, common among patients with obesity and type 2 diabetes, and pancreatic cancer.
Oct 31, 2023
0
146
Loss of a single gene could be enough to cause female infertility, with research identifying that women won't make eggs without the protein it produces.
Oct 25, 2023
0
32
Results of a multicenter phase II clinical trial led by the University of Chicago Medicine Comprehensive Cancer Center show that adding an immunomodulatory agent to treatment with the targeted tyrosine kinase inhibitor (TKI) ...
Sep 1, 2023
0
52
Researchers from The University of Texas MD Anderson Cancer Center reported study results showing that the targeted therapy fruquintinib significantly improved overall survival (OS) and progression-free survival (PFS) in ...
Jun 16, 2023
0
66
Researchers at the National Institutes of Health and their colleagues have identified genomic variants that cause a rare and severe inflammatory skin disorder, known as disabling pansclerotic morphea, and have found a potential ...
May 31, 2023
0
94